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ABSTRACT
We have explored the potential for clinical implementation of ATAD2 as a 
biomarker for aggressive endometrial cancer by investigating to what extent 
immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype 
and molecular subgroups of endometrial carcinomas. Increased expression of the 
ATAD2 gene has been implicated in cancer development and progression in a number 
of tissues, but few studies have investigated ATAD2 expression using IHC. Here we 
show that high ATAD2 protein expression is significantly associated with established 
clinical-pathological variables for aggressive endometrial cancer, also in the subset of 
estrogen receptor α (ERα) positive tumors. Protein and mRNA expression of ATAD2 
were highly correlated (P < 0.001), suggesting that IHC staining may represent a 
more clinically applicable measure of ATAD2 level in routinely collected formalin 
fixed paraffin embedded specimens. Gene expression alterations in samples with high 
ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, 
CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease 
and potential for new targeting therapies. Our results support that IHC staining for 
ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and 
targetable alterations in endometrial carcinomas to be further explored in controlled 
clinical trials.
INTRODUCTION
One of today’s most important clinical challenges 
is to develop clinically applicable and robust biomarkers 
to predict prognosis and to select patients for customized 
systemic treatments more likely to be beneficiary [1, 2]. 
Endometrial cancer is one of the most common female 
cancers in industrialized countries, with rising incidence-
rate. In general, the overall prognosis is good, however 
in 15-20% of patients the disease recurs. In contrast to 
breast cancer, neither hormone receptor status, nor other 
biomarkers are currently implemented in clinical use. 
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More robust biomarkers that independently can predict 
prognosis in order to improve treatment of endometrial 
cancer need to be developed [3].
One of the hallmarks of cancer is sustained 
proliferation. Altered gene expression of regulators 
of proliferation or reprogramming of distinct cellular 
pathways allows the cancer cell to bypass normal cell 
cycle control. The gene ATAD2 (ATPase family, AAA 
domain containing 2; also listed as ANCCA, pro2000) 
is predominantly expressed in male germ cells, but 
becomes overexpressed in several cancer forms. It was 
initially identified as a target gene of the proto-oncogene 
AIB1 and as a transcriptional coactivator of ERα in 
breast cancer cells [4]. Further studies demonstrated 
that ATAD2 is overexpressed in several types of human 
cancers, including breast cancer, prostate cancer and lung 
cancer [4-8]. Moreover, its elevated transcripts were early 
included in a number of prognostic cancer-gene signatures 
that are linked to cancer development and progression such 
as increased risks of distant metastasis in breast cancer [9, 
10] and disease recurrence in endometrial cancer [11].
The ATAD2 protein acts as a transcriptional co-
regulator, both in hormone dependent gene transcription 
through its interactions with the hormone receptors ER 
and AR [12], and in transcriptional regulation by E2Fs and 
MYC through their direct interaction [6, 13]. In hormone 
dependent cancer cells ATAD2 is an estrogen and androgen 
responsive gene and also a co-activator for full activity of 
ER and AR [4, 14]. The ATAD2 protein has also received 
attention due to its “drugable” composition. In addition 
to its N-terminal part that interacts with E2F and AR, 
ATAD2 consists of a bromodomain capable of binding 
to acetylated histones, and the AAA ATPase domain 
that possesses ATPase activity and mediates protein 
multimerization [4, 5, 13]. Both the bromodomain and the 
AAA ATPase domain could be targeted by small molecule 
inhibitors, and the recent chemical synthesis of the ATAD2 
bromodomain could facilitate further studies of the 
function of the protein [15]. Combined with its apparent 
wide overexpression in cancers, this leaves ATAD2 as a 
promising target for therapy in several cancers and calls 
for further investigations of its expression in specific 
cancer types.
Few studies have investigated ATAD2 protein 
expression by IHC, mainly due to lack of commercially 
available specific antibodies. We here apply an antibody 
previously shown to specifically detect ATAD2 expression 
in breast cancer [7] to explore the potential for clinical 
implementation of ATAD2 as a biomarker for aggressive 
disease in endometrial cancer. We have investigated 
to what extent IHC staining for ATAD2 is feasible, 
reflects clinical phenotype and molecular subgroups of 
endometrial carcinomas. To shed light on the biological 
processes involved in cancers with high ATAD2 protein, 
gene expression analyses were performed in parallel. 
Our results support ATAD2 as a prognostic marker in 
endometrial cancer, and also imply that ATAD2 might be 
a promising predictive marker for specific treatment in the 
future.
RESULTS
Increased ATAD2 expression associates with more 
aggressive stages of disease and is correlated to 
copy-number alterations
High ATAD2 expression has been linked to 
aggressive disease in breast cancer and endometrial 
cancer but little is known regarding the variation in ATAD2 
mRNA expression related to different stages of disease 
development for endometrial cancer. We investigated 
the mRNA levels of ATAD2 in a unique collection of 
fresh tissue from 18 precursor cancer lesions (complex 
atypical hyperplasias, CAHs), 141 primary endometrial 
cancer lesions of the endometrioid subtype and 34 of 
non-endometrioid subtypes, as well as 42 metastatic 
lesions (Figure 1). We find that the expression of ATAD2 
increases in early stages of cancer progression, with a 
significant increase in ATAD2 expression from CAH 
lesions to grade 1 endometrioid lesions (P < 0.001) and 
a further significant increase from grade 1/2 to grade 3 
endometrioid endometrial cancers (P < 0.001). ATAD2 
mRNA levels are equally high in grade 3 endometrioid 
lesions, non-endometrioid and metastatic lesions. We have 
previously shown by SNP analyses of 70 cases that the 
Figure 1: ATAD2 mRNA expression is elevated in 
aggressive stages of endometrial cancer. A significant 
increase in ATAD2 expression was found from complex atypical 
hyperplasias (CAH; n = 18) to grade 1 (n = 49) endometrioid 
endometrial carcinomas (EEC) (P < 0.001), with a further 
increase from grade 2 (n = 53) to grade 3 (n = 39) EECs (P < 
0.001). Non-endometrioid (NEEC, n = 34) tumors showed the 
same high levels of ATAD2 as grade 3 EEC. ATAD2 expression 
is high in metastases from both EECs (n = 22) and NEECs (n = 
19). 
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increase in ATAD2 associates with amplification of the 
8q24 region [16]. To further explore possible underlying 
mechanisms for increased ATAD2 levels we utilized 
publicly available data from the The Cancer Genome Atlas 
(TCGA) consortium to investigate specific ATAD2 copy 
number alterations and DNA methylation status of ATAD2. 
In the pan cancer dataset, accessed through the TCGA 
copy number portal, ATAD2 was frequently amplified in 8 
out of 11 total cancer types (including endometrial cancer, 
Supplementary Table S1), with the overall frequency of 
amplification of 31%. However, these amplifications were 
not due to the ATAD2 gene specifically being amplified, 
but rather larger regions within the 8q24 region containing 
the gene. The event of deletions (frequency of 2%) was not 
significant in any cancers across the pan cancer dataset. To 
explore ATAD2 alterations in detail for endometrial cancer, 
putative copy-number alterations (GISTIC-based analysis 
[17]), showed a highly significant correlation of increased 
copy-number levels and mRNA expression of ATAD2 
for endometrial cancer, confirming previous findings 
that ATAD2 amplification leads to higher expression of 
ATAD2 (Supplementary Figure S1A). In contrast, when 
investigating the DNA methylation status of ATAD2 
(through 13 specific ATAD2 probes available in the k450 
DNA methylation dataset from TCGA), we found the gene 
to be almost completely hypomethylated, suggesting that 
loss of DNA methylation is not a plausible mechanism 
providing elevated ATAD2 levels in endometrial cancer 
(Supplementary Figure S1B).
Immunohistological staining of ATAD2 is 
associated with reduced disease-specific survival, 
and correlates well with mRNA expression levels
To investigate the prognostic impact of ATAD2 
protein level in endometrial cancer, 564 primary tumors 
were stained by immunohistochemistry. ATAD2 is 
detected in the nuclei of cancer cells, with little staining in 
cytoplasm or surrounding stromal tissue (Figure 2). Only 
nuclear staining was recorded. 50% of all cases showed 
low expression (Index 0, 1 and 2; Figure 2A and 2B), 32% 
showed intermediate expression (Index 3 and 4; Figure 
2C and 2D) and 18% showed high expression (Index 
6 and 9; Figure 2E and 2F) of ATAD2. For subsequent 
analyses, intermediate and high expression groups were 
combined according to similar survival pattern. Details 
regarding scoring of ATAD2 are given in the method 
section. When comparing ATAD2 expression with clinical 
and histopathological variables for aggressive endometrial 
cancer, we find a highly significant association between 
high ATAD2 expression and high FIGO (International 
Federation of Gynecology and Obstetrics) stage, non-
endometrioid subtype, high grade and aneuploidy (Table 
1; all P-values ≤0.001). ATAD2 expression is also 
negatively correlated with protein expression of hormone 
receptors ERα (P < 0.001), PR (P < 0.001) and Androgen 
Receptor (AR; P = 0.009), indicating that ATAD2 may 
be a biomarker relevant to identify patients unlikely to 
respond to antihormonal treatment. In survival analysis 
(Figure 3A), high ATAD2 significantly predicts poor 
disease-specific survival in univariate analysis (P < 0.001). 
The validity and robustness of antibodies to detect 
prognostic biomarkers is debated due to the possibility for 
unspecific staining. Expression data from 155 overlapping 
patients is available from microarrays of the 564 patients 
explored for protein level by immunohistochemistry. We 
find a highly significant correlation between mRNA and 
protein levels (P < 0.001, Figure 3B) supporting that 
immunohistochemical staining adequately reflects mRNA 
level. In line with this, grouping mRNA in accordance 
with IHC median cutoff into two equal patient groups 
is significantly associated with poor prognosis, with a 
5-years disease specific survival of 72% compared to 88% 
for patients with high ATAD2 mRNA (p = 0.006). For 
Figure 2: Immunohistochemical detection of ATAD2 
protein in endometrial carcinomas. ATAD2 was mainly 
nuclear, with low expression detected in 50% of all cases (A.; 
B. high magnification). 32% of the cases showed intermediate 
expression (C.; D. high magnification) and 18 % had high 
expression of ATAD2 (E.; F. high magnification). Details 
regarding IHC staining and scoring are given is the methods. Bar 
= 100µm for A, C and E, Bar = 50µm for B, D and F
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mRNA, applying the upper quartile limit demonstrates to 
have an even stronger prognostic impact with a 5-years 
disease specific survival of 58% compared to 88% for 
patients with high ATAD2 mRNA (P < 0.001, Figure 3C) 
suggesting a potential for using mRNA assessment as an 
even stronger prognostic marker, although currently less 
applicable in a routine clinical setting. This is in line with 
our previous observation in a smaller dataset [16]. Taken 
together, our findings support that immunohistochemical 
staining for ATAD2 represent a clinically applicable 
method to measure phenotype relevant ATAD2 level 
in endometrial carcinomas, also with the advantage of 
morphologic assessment during the IHC analysis. 
ATAD2 is associated with poor prognosis in the 
subgroup of ER positive endometrial cancers, and 
is an independent marker for poor prognosis in 
endometrioid endometrial cancer patients
We investigated the potential of ATAD2 as a 
biomarker for poor prognosis within subgroups of 
Table 1: ATAD2 protein expression in prospectively collected tumors related to 
clinico-pathologic factors in 564 patients with endometrial carcinoma
Oncotarget28444www.impactjournals.com/oncotarget
Figure 3: ATAD2 predicts poor prognosis in endometrial cancer. High expression of ATAD2 protein significantly predicts 
poor prognosis in endometrial cancer compared to low ATAD2 expression A.. Patients with high ATAD2 protein levels (n = 76) have 
significantly higher ATAD2 mRNA expression than patients with low ATAD2 protein expression (n = 79) B.. Poor outcome is also predicted 
by high ATAD2 mRNA levels, defined as the upper quartile C. Number in brackets in figure A and C represents number of disease specific 
deaths in each group.
Figure 4: ATAD2 is a prognostic marker in subgroups of endometrial cancer. High expression of ATAD2 identifies patients 
with poorer survival within the ERα positive subgroup A., the ERα-negative subgroup B. and also in the endometrioid only subgroup C.. 
Number in brackets represents number of disease specific deaths in each group.
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Table 2: ATAD2 protein expression in prospectively collected tumors related to clinico-
pathologic factors in 423 Estrogen Receptor α positive patients with endometrial carcinoma
Table 3: Multivariable survival analyses of endometrioid endometrial cancer patients according to 
Cox’ proportional hazards regression model 
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endometrial cancer. We found ATAD2 to significantly 
predict poor survival in both ERα positive (Figure 4A) 
and ERα negative (Figure 4B) patients. ATAD2 has been 
suggested as a cofactor for ERα and therefore we focused 
specifically on the prognostic impact of ATAD2 in the 
ERα positive subgroup of patients. Interestingly, we find 
that high ATAD2 is significantly associated with reduced 
disease-specific survival (Figure 4A) and correlates with 
non-endometrioid type, high grade, aneuploidy and loss 
of PR receptor (all P-values≤0.002; Table 2) also in the 
subgroup of ERα positive patients. 
ATAD2 also proved to be significantly associated 
with poor survival for patients with endometrioid 
histology (Figure 4C). Cox analysis was performed for 
the endometrioid subgroup since an interaction between 
FIGO stage and histologic type was suspected. We find 
that ATAD2 independently predicts poor survival in 
the endometrioid subgroup, in a Cox regression model 
adjusting for age, FIGO stage and grade (Table 3). 
Primary tumors with high ATAD2 demonstrate 
changes in cell cycle regulation and enrichment 
for B-MYB-associated pathways
When examining the most significantly upregulated 
genes in primary tumors with high ATAD2 protein levels 
(false discovery rate; FDR < 0.05 in SAM analysis), 
several key regulators of cell proliferation are amongst 
the top 100 regulated genes (Supplementary Table S2). 
Amongst these are genes directly linked to mitosis, cell 
division and cell signaling. For endometrial carcinoma 
patients with high ATAD2 levels, 9 out of 20 genes known 
to be directly regulated by ATAD2 in breast cancer [7], 
are found to be highly expressed (highlighted in red and 
listed in Supplementary Table S2). We further explored 
the Connectivity Map database using this genelist to 
search for drugs with treatment potential for the patient 
group with high ATAD2 protein level, identifying HDAC 
and PI3K-pathway inhibitors amongst the to ranked 
drugs (Supplementary Table S3). To further explore the 
molecular signaling pathways altered in tumors with high 
ATAD2 protein levels, GSEA analysis was performed. 
Tumors with high ATAD2 protein levels show signs 
of increased proliferation, with gene sets linked to cell 
cycle in the C5 MSigDB collection (Gene Ontology gene 
sets) highly enriched (Table 4, top panel). To gain more 
insight in the molecular processes underlying this, we also 
explored the C2 MSigDB, representing curated gene sets 
generated from online pathway databases and PubMed 
publications. Among the four gene sets significantly 
enriched (FDR < 0.05) in tumors with high ATAD2, three 
gene sets pointed to B-MYB; the two B-MYB gene sets 
published by Shepard et al [18], as well as the TFRC 
targets dn published by O’Donnell et al [19]. In addition 
one gene set linked to prostaglandin and E2 response 
was significantly enriched in patients with high ATAD2. 
To validate the link between high ATAD2 and B-MYB 
Table 4: Gene sets significantly enriched in patients with high ATAD2 protein expression in gene 
set enrichment analysis (GSEA)
Rank Gene set name-MSigDB C5 n NES FDR*
1 Mitotic Cell Cycle 139 2.12 0.022
2 Cell Cycle Process 174 2.08 0.025
3 Cell Cycle Phase 155 2.05 0.024
4 Interphase 64 2.04 0.023
5 M-phase of mitotic cell cycle 78 2.0 0.034
6 Interphase of mitotic cell cycle 58 2.0 0.028
7 M-phase 102 2.0 0.025
8 S-phase 12 1.99 0.030
9 Mitosis 76 1.98 0.029
10 Cell cycle 288 1.95 0.041
11 DNA dependent DNA replication 47 1.95 0.040
12 Cell cycle checkpoint 44 1.94 0.041
*Gene sets with FDR<0.05 included
Rank Gene set name- MSigDB C2 n NES FDR
1 Shepard BMYB targets [18] 66 2.21 0.026
2 Shepard BMYB morpholino DN [18] 181 2.19 0.016
3 Chemnitz response to prostaglandin E2 UP [35] 124 2.18 0.015
4 ODonnell TFRC targets DN [19] 118 2.12 0.038
5 Dutertre estradiol response 24HR UP [36] 294 2.09 0.057
6 Kaufmann DNA replication genes [37] 132 2.08 0.054
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signaling pathways, we explored a publically available 
external dataset confirming similar enrichment for two 
B-MYB gene sets and the TFRC targets dn all being 
amongst the top 5 ranked gene sets related to high ATAD2 
level (Supplementary Table S4). 
It has been proposed that elevation of ATAD2 
may lead to a loop of transcriptional overexpression of 
its downstream targets such as E2Fs and ATAD2 itself 
[13]. ATAD2 is both a target for, and interacts with E2F, 
regulating its activity. The E2Fs transcription factors direct 
transcription of B-MYB (gene name MYBL) during cell 
cycle progression [20]. To explore this reported relation 
in different stages of endometrial cancer, we examined 
the mRNA levels separately in CAHs, primary tumors 
and metastatic lesions. We find a consistent and highly 
significant correlation between the gene levels for ATAD2 
and E2F1, E2F2 and MYBL during all stages of disease 
from precursors to metastatic lesions (Figure 5). ATAD2 
amplification is most often seen in the Copy number high 
(serous like) subtype of the TCGA molecular subclasses 
(Supplementary Figure S2 A and B). This same pattern is 
also observed for E2F1 and MYBL2, located close to the 
Figure 5: Expression of ATAD2 strongly correlates with E2Fs and MYBL2 levels. The mRNA levels of the transcription 
factors E2F1 and E2F2 as well as their downstream target MYBL2 (protein name B-MYB) is strongly correlated with expression levels 
of ATAD2. These patterns for strong correlations are consistently seen during tumor development from precursor lesions of endometrial 
cancer, complex atypical hyperplasias (A.-C.; n = 18), through primary tumors (D.-F.; n = 176) to metastatic lesions (G.-I.; n = 42).
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region 20q13 often amplified in the serous like molecular 
sub group of endometrial cancer [11], indicating that in 
addition to a transcriptional link, these genes may also be 
co-amplified due to general genomic instability. 
DISCUSSION
Recent studies suggest that ATAD2 is overexpressed 
in several cancers and that ATAD2 may have a potential 
both as a biomarker and as a therapeutic target. We have 
previously identified and also recently validated ATAD2 
as one of 29 genes predicting recurrence in an endometrial 
cancer recurrence score [11, 21]. Also ATAD2 mRNA level 
has been linked to MYC expression and amplification of 
the 8q24 region [16]. Here, we further explore expression 
of ATAD2 mRNA and the protein levels of ATAD2 by 
IHC and investigate its potential as a prognostic marker 
in endometrial cancer. We find that ATAD2 is low in 
CAH lesions, in line with the apparent no expression 
in normal uterine tissue [5]. Compared to the precursor 
lesions CAH, we see a significantly increase in ATAD2 
in grade 1 endometrioid cancers with a further increase 
to grade 3 endometrioid endometrial cancers. ATAD2 
levels are high also in non-endometrioid endometrial 
cancers and metastatic lesions. The mechanism involved 
in the observed increase in ATAD2 level during cancer 
development is only partially understood. Elevated 
levels of ATAD2 have been linked to gene amplification. 
Although DNA methylation could represent an additional 
mechanism contributing to increased expression, we do not 
find sufficient evidence that this is the case investigating 
publically available TCGA data. This is contrasting the 
significant association between the increase in mRNA 
expression and increase in gene copy number, supporting 
that gene copy number changes are the most dominant 
mechanism causing the elevated expression of ATAD2 
observed in endometrial cancers.
We have applied the previously validated antibody 
to detect ATAD2 protein expression in endometrial cancer 
in relation to clinico-pathological parameters. We find 
that high expression of ATAD2 predicts poor outcome 
and significantly associates with markers for aggressive 
endometrial cancer, such as high FIGO stage and high 
grade, non-endometrioid type, and loss of hormone 
receptors AR, PR and ERα. This is in line with findings 
from breast cancer, where high ATAD2 detected by IHC 
is associated with aggressive disease [7]. We find ATAD2 
to be an independent prognostic marker in endometrioid 
tumors and high ATAD2 corresponds with aggressive 
disease for ERα positive patients. ATAD2 has been 
described as an estrogen and androgen responsive gene 
in hormone dependent cancer cells and a co-activator for 
full activity of ER and AR [4, 14], contributing to cancer 
related proliferation. Our results may point to a similar 
regulation of ATAD2 also in endometrial cancer. However, 
additional mechanistic impact by ATAD2 is evident given 
its high expression detected also in the often ER negative 
non-endometrioid tumors. 
Molecular profiling of patients according to ATAD2 
level was performed to explore genetic alterations 
associated with increase in ATAD2 expression. In 
concordance with findings from breast cancer [7] we 
find that ATAD2 overexpression correlate strongly 
with expression of genes associated with increased 
proliferation, suggesting that ATAD2 either act as an 
upstream mediator of their expression or as a collaborator 
of their function. GSEA analyses using the GO gene sets 
(MSigDB C5) showed enrichment of gene sets linked 
to cell proliferation in patients with high ATAD2 levels 
(Table 4). A more specific GSEA analysis using curated 
data sets (MSigDB C2) identified gene sets linked to 
B-MYB signatures [18] as well as TFRC (Transferrin 
receptor) and estradiol treatment as enriched in patients 
with high ATAD2 in our patient cohort. This was validated 
in an external dataset. In SAM analyses of primary tumors 
we also found B-MYB (listed as MYBL2), E2F1 and 
E2F2 to be amongst the top 20 up regulated genes in 
primary tumors with high ATAD2. This strong association 
of expression of E2F1, E2F2 and MYBL2 with ATAD2 is 
found in both CAHs, primary and metastatic endometrial 
cancer lesions, indicating that the expression of these 
genes are tightly linked in all stages of endometrial 
cancer. This is interesting, since links between ATAD2, 
B-MYB and E2Fs has been reported also in other cancers. 
In breast cancer, E2F1 protein regulates ATAD2 gene 
expression [6] and B-MYB has been reported to have 
a role in ATAD2 driven cell proliferation [7]. B-MYB 
belongs to the MYB family of transcription factors and is 
involved in regulation of cell cycle at several levels [22]. 
B-MYB is also shown to cooperate with E2F transcription 
factors to regulate genes important for G
2
/M transition 
[20]. Also in prostate cancer E2F1 binds the ATAD2 gene 
regulatory region to activate its gene transcription [23]. A 
similar relationship between E2Fs, ATAD2 and B-MYB 
has not been investigated in endometrial cancer. However 
our data support that these genes cooperate to drive 
proliferation, resulting in aggressive disease. As already 
shown in breast cancer, we also find several members of 
the Kinesin protein family (KIF11, KIF15, KIF23, KIF2C 
and KIFC1) to be upregulated in patients with high 
expression of ATAD2. Kinesins have important roles in 
cell division and signaling, and ATAD2 has been shown 
to regulate expression of key kinesin members, both in 
the presence and absence of estrogen in breast cancer cell 
lines [24]. Aberrant expression of kinesins has also been 
linked to resistance to taxol treatment and attempts have 
been made to target these proteins in cancer [25]. Given 
the high number of kinesins with altered expression in 
our study, a more detailed study should be undertaken to 
pinpoint the specific role of the different family members 
in endometrial cancer. 
Several prognostic gene signatures defined in cancer 
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include ATAD2. Some have been prospectively validated 
to reflect poor outcome [21]. In addition, we and others 
have shown that increased ATAD2 may predict survival, 
and we here confirm that ATAD2 protein assessed by 
IHC is an independent prognostic marker in endometrioid 
endometrial cancer patients. Combined with the increased 
efforts to target bromodomain-containing proteins in 
cancer [15, 26], ATAD2 seems an attractive cancer protein 
for more detailed studies. It is also interesting that our 
molecular analyses point to PI3K-pathway and HDAC 
inhibitors as potential drugs for treatment of patients with 
high ATAD2. This is in line with previous observations 
regarding treatment of aggressive molecular subclasses 
of endometrial cancers, but needs further validation in a 
clinical setting, possibly alongside validation of ATAD2 
as a biomarker for endometrial cancer.
The molecular mechanisms underlying the 
aggressive behavior of tumors with high ATAD2 is still 
poorly understood in endometrial cancer. However 
our data points to changes in regulators of cell cycle 
progression as potential key players. Identifying the 
relationship between these as well as the other major 
downstream effectors may point to development and/or 
testing of novel therapeutics in endometrial carcinoma 
clinical trials. 
MATERIALS AND METHODS
Ethics statement
All parts of the study have been approved according 
to Norwegian legislation as well as international demands 
for ethical review. Patients were included in the study 
after written informed consent approved by the ethics 
committee (REK West). The study was approved by the 
Norwegian Data Inspectorate, Norwegian Social Sciences 
Data Services, and the Western Regional Committee 
for Medical and Health Research Ethics, REC West 
(NSD15501; REK 052.01). 
Tumor specimens
A patient series counting 585 patients diagnosed 
with primary endometrial carcinoma in Hordaland County 
(Norway) during the period 2001-2012 were prospectively 
collected. Patients were staged according to FIGO 2009 
criteria and age at diagnosis, histologic type, histologic 
grade, treatment and follow-up were obtained from 
the clinical records and routine histopathology reports 
from a tumor board setting. Formalin-fixed paraffin-
embedded (FFPE) tissue from 564 patients was used for 
immunohistochemistry, while fresh frozen tissues from 18 
CAH, 176 primary endometrial cancers (155 overlapping 
with TMA cases) and 42 metastatic lesions were available 
for mRNA extraction. The metastatic lesions were from 
31 individual patients, where 26 patients had available 
tissue from both the primary lesion and the metastases in 
parallel. 6 metastatic lesions from 5 individual patients 
missing a primary tumor counterpart, were also included 
in the analyses. Detailed information on the metastatic 
samples is included in Supplementary Table S5.
External datasets
ATAD2 gene copy number alterations and ATAD2 
methylation status in relation to mRNA levels were 
investigated using the publicly available endometrial 
carcinoma data from The Cancer Genome Atlas 
(TCGA). Data was downloaded through the Cancer 
Browser (https://genome-cancer.ucsc.edu. Dataset 
details: DNA methylation (hMethyl450_2014-05-02), 
RNA expression (exp_GAV2_2014-08-28) and CNA 
(gistic2thd_2014-08-22).
For external validation of findings in microarray 
analyses, a dataset from 111 tumors was obtained from 
the Expression Project for Oncology (expO: http://www.
intgen.org). Gene Expression Omnibus (GEO) accession 
numbers and information on clinico-pathologic data as 
well as processing of this dataset to construct transcript 
level probe sets have previously been described [11, 27]. 
Immunohistochemistry
FFPE tissue from 564 patients was used to construct 
tissue microarrays (TMAs) as previously described [28]. 
Briefly, three cylinders of 0.6 mm were retrieved from 
high tumor purity areas using a custom-made precision 
instrument (Beecher Instruments, Silver Spring, MD, 
USA) and mounted in a paraffin block. TMA sections 
(5µm) were stained for ATAD2 expression using a 
validated antibody and a protocol described previously 
[7]. AR expression was detected using ab133273 
(Abcam) diluted 1:100 for 1 hour at room temperature 
followed by 30 min incubation with secondary HRP-
conjugated antibody. Diaminobenzidine was applied 
for 8 min, before counterstained with hematoxylin. The 
immunostained sections were scored visually by light 
microscopy, blinded for the patients clinical characteristics 
and outcome, using a semi quantitative and subjective 
method described in more detail previously [29]. Tumor 
tissue in all three cylinders were assessed to estimate the 
average protein staining. Briefly, a staining index was 
calculated as a product of staining intensity (0-3) and area 
of positive tumor cells (1≤10%, 2 = 10-50% and 3≥50%). 
In subsequent statistical analyses, indexes were grouped 
according to similarity in survival and considering the 
size of the subgroups and the number of events in each 
category. Index 0-2 (n = 281) was considered low, index 
3-9 (n = 283) was considered high. Hormone receptor 
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status was defined by IHC and recorded using the same 
soring system. Index 0-2 was defined as ERα negative 
status while index 3-9 as ERα positive. For PR and AR 
status, index 0 was considered negative while index 1-9 
positive. Details related to scoring methods applied and 
approaches to cut point development for ER and PR 
hormone receptor status have been reported previously 
[30, 31]. P53 protein expression status was available for 
383 patients with ATAD2 protein status. P53 IHC protocol 
and scoring has been published previously [32]. 
Gene expression analyses
Gene expression alterations in relation to ATAD2 
expression were investigated in fresh tissues from 18 
CAH, 176 primary endometrial cancers and 42 metastatic 
endometrial cancer lesions derived from 31 patients. 
Expression data from a subset of these patients from 122 
of the primary tumors and 19 metastases have previously 
been explored in relation to copy number changes for 
the MYC region in endometrial cancer [16]. Samples 
were validation for high tumor cell content [33]. Areas 
with necrosis were avoided. RNA was extracted using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
hybridised to Agilent Whole Human Genome Microarrays 
44k (Cat.no. G4112F), according to the manufacturer’s 
instructions. Microarrays were scanned using the Agilent 
Microarray Scanner Bundle. Normalization of raw data 
and expression analyses were performed using J-Express 
software (Molmine, Bergen, Norway). Expression data 
were quantile normalized. Median spot signal was used 
as intensity measure. For survival analyses using mRNA 
values, values were grouped either according to IHC 
cutoff (two equally sized patient groups) or in quartiles, 
where the upper quartile was defined as high expression. 
Differentially expressed genes in tumors with high levels 
of ATAD2, detected by IHC, were identified using the 
Significance Analysis of Microarray (SAM) method. 275 
genes were identified with False discovery rate (FDR) 
value < 0.05. Two class unpaired gene set enrichment 
analysis (GSEA) was performed using SAM score as 
scoring method and balanced sample permutations. The 
Molecular signature database v4.0 (MSigDB) C2 Curated 
gene set collection and C5 GO gene sets were used (http://
www.broadinstitute.org/gsea/msigdb/index.jsp). Only 
gene sets with FDR < 0.05 was considered significantly 
enriched. To validate the findings from our dataset, an 
external dataset with mRNA values from 111 endometrial 
cancer patients was investigated to compare transcriptional 
alterations related to high versus low ATAD2 level. Given 
the high correlation between ATAD2 protein measured 
with IHC and mRNA levels found in our dataset, median 
level of ATAD2 was defined as cut point in the external 
dataset in accordance with detected IHC cutoff. The 
correlation between global gene expression pattern and 
potential new therapeutics for tumors with high ATAD2 
protein was assessed using the drug signatures database 
Connectivity Map [34] as previously described [27]. The 
microarray data is publicly available at ArrayExpress, with 
accession number E-MTAB-2532.
Statistical analysis
Statistical analyses were done using IBM SPSS 
Statistics software version 21 (IBM, Armonk, NY, USA). 
All tests were two sided, and probability of < 0.05 was 
considered statistically significant. For categorical 
variables groups were compared using Pearson chi-square 
test, and Mann-Whitney U test was used to test correlations 
for continuous variables. Univariate survival analyses 
of time to death due to endometrial carcinoma (disease 
specific survival) were performed using the Kaplan-Meier 
(product-limit) method. Entry date was defined as date 
of primary surgery, and patients who died from other 
causes were censored at the date of death. Differences 
in survival between groups were estimated by the log-
rank (Mantel Cox) test. The prognostic impact of ATAD2 
adjusted for other prognostic markers was evaluated 
by the Cox proportional hazard regression models. All 
variables included were examined by log minus log plots 
to assure that the assumptions of proportional hazards 
were satisfied. Since an interaction between histologic 
type and FIGO stage was suspected, the Cox analysis was 
performed for the endometrioid subgroup. 
ACKNOWLEDGMENTS
We thank Ellen Valen, Britt Edvardsen, Kadri 
Madissoo, Bendik Nordanger and Hua My Huang for 
technical assistance. 
FUNDINGS
This study was supported by Bergen Research 
Foundation, Helse Vest, The University of Bergen, The 
Norwegian Cancer Society and The Research Council of 
Norway, and in part by NIH grant DK060019 (to H.W.C.). 
CONFLICTS OF INTERESTS
No potential conflicts of interest
REFERENCES
1. La Thangue NB and Kerr DJ. Predictive biomarkers: a 
paradigm shift towards personalized cancer medicine. 
Nature reviews Clinical oncology. 2011; 8:587-596.
2. Cancer Genome Atlas Research N, Kandoth C, Schultz 
N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson 
AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, 
Ding L, Zhang W, Mills GB, et al. Integrated genomic 
Oncotarget28451www.impactjournals.com/oncotarget
characterization of endometrial carcinoma. Nature. 2013; 
497:67-73.
3. Salvesen HB, Haldorsen IS and Trovik J. Markers for 
individualised therapy in endometrial carcinoma. The 
Lancet Oncology. 2012; 13:e353-361.
4. Zou JX, Revenko AS, Li LB, Gemo AT and Chen HW. 
ANCCA, an estrogen-regulated AAA+ ATPase coactivator 
for ERalpha, is required for coregulator occupancy and 
chromatin modification. Proc Natl Acad Sci U S A. 2007; 
104:18067-18072.
5. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle 
V, Barbry P, Debernardi A, Brambilla C, Brambilla E, 
Rousseaux S and Khochbin S. Functional characterization 
of ATAD2 as a new cancer/testis factor and a predictor of 
poor prognosis in breast and lung cancers. Oncogene. 2010; 
29:5171-5181.
6. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, 
McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen 
J and Helin K. ATAD2 is a novel cofactor for MYC, 
overexpressed and amplified in aggressive tumors. Cancer 
Res. 2009; 69:8491-8498.
7. Kalashnikova EV, Revenko AS, Gemo AT, Andrews 
NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and 
Chen HW. ANCCA/ATAD2 overexpression identifies 
breast cancer patients with poor prognosis, acting to drive 
proliferation and survival of triple-negative cells through 
control of B-Myb and EZH2. Cancer Res. 2010; 70:9402-
9412.
8. Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres 
J, Validire P, Girard P, Camilleri-Broet S, Vaylet F, 
Leroy-Ladurie F, Soria JC and Fouret P. A comparative 
and integrative approach identifies ATPase family, AAA 
domain containing 2 as a likely driver of cell proliferation in 
lung adenocarcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 
2012; 18:5606-5616.
9. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart 
AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, 
Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, 
Linsley PS, Bernards R and Friend SH. Gene expression 
profiling predicts clinical outcome of breast cancer. Nature. 
2002; 415:530-536.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, 
Yang F, Talantov D, Timmermans M, Meijer-van Gelder 
ME, Yu J, Jatkoe T, Berns EM, Atkins D and Foekens JA. 
Gene-expression profiles to predict distant metastasis of 
lymph-node-negative primary breast cancer. Lancet. 2005; 
365:671-679.
11. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, 
Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik 
J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, 
Zander T, et al. Integrated genomic profiling of endometrial 
carcinoma associates aggressive tumors with indicators of 
PI3 kinase activation. Proc Natl Acad Sci U S A. 2009; 
106:4834-4839.
12. Hsia EY, Goodson ML, Zou JX, Privalsky ML and Chen 
HW. Nuclear receptor coregulators as a new paradigm for 
therapeutic targeting. Advanced drug delivery reviews. 
2010; 62:1227-1237.
13. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX and 
Chen HW. Chromatin loading of E2F-MLL complex 
by cancer-associated coregulator ANCCA via reading a 
specific histone mark. Mol Cell Biol. 2010; 30:5260-5272.
14. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung 
HJ and Chen HW. Androgen-induced coactivator ANCCA 
mediates specific androgen receptor signaling in prostate 
cancer. Cancer Res. 2009; 69:3339-3346.
15. Creech GS, Paresi C, Li YM and Danishefsky SJ. Chemical 
synthesis of the ATAD2 bromodomain. Proc Natl Acad Sci 
U S A. 2014; 111:2891-2896.
16. Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata 
S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody 
SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, 
Mesirov JP, et al. Integrated genomic analysis of the 8q24 
amplification in endometrial cancers identifies ATAD2 as 
essential to MYC-dependent cancers. PLoS One. 2013; 
8:e54873.
17. Mermel CH, Schumacher SE, Hill B, Meyerson ML, 
Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive 
and confident localization of the targets of focal somatic 
copy-number alteration in human cancers. Genome biology. 
2011; 12:R41.
18. Shepard JL, Amatruda JF, Stern HM, Subramanian A, 
Finkelstein D, Ziai J, Finley KR, Pfaff KL, Hersey C, Zhou 
Y, Barut B, Freedman M, Lee C, Spitsbergen J, Neuberg D, 
Weber G, et al. A zebrafish bmyb mutation causes genome 
instability and increased cancer susceptibility. Proc Natl 
Acad Sci U S A. 2005; 102:13194-13199.
19. O’Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, 
Thomas-Tikhonenko A and Dang CV. Activation 
of transferrin receptor 1 by c-Myc enhances cellular 
proliferation and tumorigenesis. Mol Cell Biol. 2006; 
26:2373-2386.
20. Zhu W, Giangrande PH and Nevins JR. E2Fs link the 
control of G1/S and G2/M transcription. The EMBO 
journal. 2004; 23:4615-4626.
21. Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, 
Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst 
F, Mjos S, Halle MK, Mannelqvist M, Mauland KK, 
Oyan AM, Stefansson IM, et al. Endometrial Carcinoma 
Recurrence Score (ECARS) validates to identify aggressive 
disease and associates with markers of epithelial-
mesenchymal transition and PI3K alterations. Gynecologic 
oncology. 2014;134:599-606.
22. Sala A. B-MYB, a transcription factor implicated in 
regulating cell cycle, apoptosis and cancer. European 
journal of cancer. 2005; 41:2479-2484.
23. Altintas DM, Shukla MS, Goutte-Gattat D, Angelov D, 
Rouault JP, Dimitrov S and Samarut J. Direct cooperation 
Oncotarget28452www.impactjournals.com/oncotarget
between androgen receptor and E2F1 reveals a common 
regulation mechanism for androgen-responsive genes in 
prostate cells. Mol Endocrinol. 2012; 26:1531-1541.
24. Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen 
CZ, Li JJ and Chen HW. Kinesin family deregulation 
coordinated by bromodomain protein ANCCA and histone 
methyltransferase MLL for breast cancer cell growth, 
survival, and tamoxifen resistance. Mol Cancer Res. 2014; 
12:539-549.
25. Liu X, Gong H and Huang K. Oncogenic role of kinesin 
proteins and targeting kinesin therapy. Cancer science. 
2013; 104:651-656.
26. Philpott M, Rogers CM, Yapp C, Wells C, Lambert JP, 
Strain-Damerell C, Burgess-Brown NA, Gingras AC, 
Knapp S and Muller S. Assessing cellular efficacy of 
bromodomain inhibitors using fluorescence recovery after 
photobleaching. Epigenetics & chromatin. 2014; 7:14.
27. Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland 
E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, 
Stefansson IM, Oyan AM, Kalland KH, Akslen LA and 
Salvesen HB. Lack of estrogen receptor-alpha is associated 
with epithelial-mesenchymal transition and PI3K alterations 
in endometrial carcinoma. Clinical cancer research : an 
official journal of the American Association for Cancer 
Research. 2013; 19:1094-1105.
28. Stefansson IM, Salvesen HB and Akslen LA. Prognostic 
impact of alterations in P-cadherin expression and related 
cell adhesion markers in endometrial cancer. Journal of 
clinical oncology : official journal of the American Society 
of Clinical Oncology. 2004; 22:1242-1252.
29. Salvesen HB, Das S and Akslen LA. Loss of nuclear 
p16 protein expression is not associated with promoter 
methylation but defines a subgroup of aggressive 
endometrial carcinomas with poor prognosis. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2000; 6:153-159.
30. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, 
Birkeland E, Raeder MB, Oyan AM, Stefansson IM, 
Kalland KH, Akslen LA and Salvesen HB. Loss of GPER 
identifies new targets for therapy among a subgroup of 
ERalpha-positive endometrial cancer patients with poor 
outcome. Br J Cancer. 2012; 106:1682-1688.
31. Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano 
K, Trovik J, Hoivik EA, Mills GB, Krakstad C and 
Salvesen HB. Loss of progesterone receptor links to high 
proliferation and increases from primary to metastatic 
endometrial cancer lesions. European journal of cancer. 
2014; 50:3003-3010.
32. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, 
Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz 
J, Tingulstad S, Staff AC, MoMa TECsg, Amant F, Akslen 
LA and Salvesen HB. Hormone receptor loss in endometrial 
carcinoma curettage predicts lymph node metastasis and 
poor outcome in prospective multicentre trial. European 
journal of cancer. 2013; 49:3431-3441.
33. Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, 
Trovik J and Salvesen HB. Stratification based on high 
tumour cell content in fresh frozen tissue promotes selection 
of aggressive endometrial carcinomas. Histopathology. 
2012; 60:516-519.
34. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel 
MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich 
M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, 
Clemons PA, et al. The Connectivity Map: using gene-
expression signatures to connect small molecules, genes, 
and disease. Science. 2006; 313:1929-1935.
35. Chemnitz JM, Driesen J, Classen S, Riley JL, Debey 
S, Beyer M, Popov A, Zander T and Schultze JL. 
Prostaglandin E2 impairs CD4+ T cell activation by 
inhibition of lck: implications in Hodgkin’s lymphoma. 
Cancer Res. 2006; 66:1114-1122.
36. Dutertre M, Gratadou L, Dardenne E, Germann S, Samaan 
S, Lidereau R, Driouch K, de la Grange P and Auboeuf D. 
Estrogen regulation and physiopathologic significance of 
alternative promoters in breast cancer. Cancer Res. 2010; 
70:3760-3770.
37. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, 
Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A and 
Sarasin A. High expression of DNA repair pathways is 
associated with metastasis in melanoma patients. Oncogene. 
2008; 27:565-573.
